Please login to the form below

Not currently logged in
Email:
Password:

'Suicide rating' on the cards for new drugs


New drugs licensed in the UK could be accompanied with a full 'suicide rating', informing how much of an effect the substance may have on the patient's suicidal feelings, according to proposals being considered by the European Medicines Agency.

New drugs licensed in the UK could be accompanied with a full 'suicide rating', informing how much of an effect the substance may have on the patient's suicidal feelings, according to proposals being considered by the European Medicines Agency (EMEA). 

European regulators will also be required to ensure that pharma companies include a comprehensive suicide assessment in trials of new drugs.

The EMEA has recently sent letters to all drug companies, requesting them to re-analyse their data in accordance with a system already developed and approved by the US Food and Drug Administration (FDA).

According to reports, the Medicines and Healthcare products Regulatory Authority (MHRA) has said that they would follow the EMEA's actions if the US tests became more widely used.

Dr Kelly Posner, a research scientist based at Columbia University, has organised and held discussions between the EMEA major pharma companies.

She has also created a comprehensive questionnaire named the 'Columbia suicide severity rating', within which drugs will be given a score out of 23 for hazardousness. The questionnaire has already been translated into 80 different languages, for use across Europe.

"All the players, the FDA, EMEA, representatives from the drug companies, will be at the meeting to discuss how to move forward," Posner told The Times newspaper.

"I've been getting requests from clinics and authorities in Europe asking how to implement the study. It's really moved the field in that way. Hopefully this will be the first step to broadening the study across Europe," Posner concluded. 

An increasing body of evidence suggest serious suicidal thoughts may be associated with certain treatments for acne, swelling, heartburn, pain, obesity, high blood pressure, cholesterol, bacterial infections, smoking cessation and insomnia.

The reform suggestions follow recent health warnings over sanofi-aventis' obesity drug Acomplia, Roche's acne drug Roaccutane and Pfizer's smoking cessation drug Champix.

14th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics